| Epidermal growth factor receptor (EGFR) pathway, yes-associated protein (YAP) and the regulation of programmed death-ligand 1 (PD-L1) in non-small cell lung cancer (NSCLC) PC Hsu, DM Jablons, CT Yang, L You International journal of molecular sciences 20 (15), 3821, 2019 | 147 | 2019 |
| YAP promotes erlotinib resistance in human non-small cell lung cancer cells PC Hsu, B You, YL Yang, WQ Zhang, YC Wang, Z Xu, Y Dai, S Liu, ... Oncotarget 7 (32), 51922, 2016 | 123 | 2016 |
| YAP regulates PD-L1 expression in human NSCLC cells J Miao, PC Hsu, YL Yang, Z Xu, Y Dai, Y Wang, G Chan, Z Huang, B Hu, ... Oncotarget 8 (70), 114576, 2017 | 111 | 2017 |
| Targeting YAP in malignant pleural mesothelioma WQ Zhang, YY Dai, PC Hsu, H Wang, L Cheng, YL Yang, YC Wang, ... Journal of cellular and molecular medicine 21 (11), 2663-2676, 2017 | 62 | 2017 |
| YAP1 regulates ABCG2 and cancer cell side population in human lung cancer cells Y Dai, S Liu, WQ Zhang, YL Yang, P Hang, H Wang, L Cheng, PC Hsu, ... Oncotarget 8 (3), 4096, 2017 | 53 | 2017 |
| Inhibition of yes‐associated protein down‐regulates PD‐L1 (CD274) expression in human malignant pleural mesothelioma PC Hsu, J Miao, YC Wang, WQ Zhang, YL Yang, CW Wang, CT Yang, ... Journal of cellular and molecular medicine 22 (6), 3139-3148, 2018 | 50 | 2018 |
| The crosstalk between Src and Hippo/YAP signaling pathways in non-small cell lung cancer (NSCLC) PC Hsu, CT Yang, DM Jablons, L You Cancers 12 (6), 1361, 2020 | 46 | 2020 |
| Cucurbitacin E inhibits the Yes‑associated protein signaling pathway and suppresses brain metastasis of human non‑small cell lung cancer in a murine model PC Hsu, B Tian, YL Yang, YC Wang, S Liu, A Urisman, CT Yang, Z Xu, ... Oncology reports 42 (2), 697-707, 2019 | 31 | 2019 |
| Inhibition of yes‐associated protein suppresses brain metastasis of human lung adenocarcinoma in a murine model PC Hsu, J Miao, Z Huang, YL Yang, Z Xu, J You, Y Dai, CC Yeh, G Chan, ... Journal of cellular and molecular medicine 22 (6), 3073-3085, 2018 | 31 | 2018 |
| Response to afatinib in treatment-naïve patients with advanced mutant epidermal growth factor receptor lung adenocarcinoma with brain metastases SH Li, CY Liu, PC Hsu, YF Fang, CC Wang, KC Kao, LC Tseng, CT Yang Expert Review of Anticancer Therapy 18 (1), 81-89, 2018 | 31 | 2018 |
| The role of yes-associated protein (YAP) in regulating programmed death-ligand 1 (PD-L1) in thoracic cancer PC Hsu, CT Yang, DM Jablons, L You Biomedicines 6 (4), 114, 2018 | 30 | 2018 |
| Consolidation treatment of durvalumab after chemoradiation in real‐world patients with stage III unresectable non‐small cell lung cancer CH Chu, TH Chiu, CC Wang, WC Chang, ACC Huang, CY Liu, CL Wang, ... Thoracic Cancer 11 (6), 1541-1549, 2020 | 29 | 2020 |
| The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring … CY Liu, CL Wang, SH Li, PC Hsu, CH Chen, TY Lin, CH Kuo, YF Fang, ... Oncotarget 8 (57), 97602, 2017 | 26 | 2017 |
| Durvalumab as consolidation therapy in post-concurrent chemoradiation (CCRT) in unresectable stage III non-small cell lung cancer patients: a multicenter observational study CC Wang, LC Chiu, JS Ju, YC Lin, YF Fang, CT Yang, PC Hsu Vaccines 9 (10), 1122, 2021 | 22 | 2021 |
| Feasibility and effectiveness of afatinib for poor performance status patients with EGFR-mutation-positive non-small-cell lung cancer: a retrospective cohort study CE Wu, CF Chang, CY Huang, CT Yang, CHS Kuo, PC Hsu, JWC Chang BMC cancer 21, 1-14, 2021 | 17 | 2021 |
| The combination of afatinib and bevacizumab in untreated EGFR-mutated advanced lung adenocarcinoma: a multicenter observational study PC Hsu, CY Huang, CC Wang, SCH Kuo, CH Chu, PH Tung, ACC Huang, ... Pharmaceuticals 13 (11), 331, 2020 | 17 | 2020 |
| Downregulation of lumican enhanced mitotic defects and aneuploidy in lung cancer cells Y Cheng-Ta, H Ping-Chih, C Shu-Er Cell Cycle 19 (1), 97-108, 2020 | 17 | 2020 |
| Risk stratification using a novel nomogram for 2190 EGFR-mutant NSCLC patients receiving the first or second generation EGFR-TKI JWC Chang, CY Huang, YF Fang, CF Chang, CT Yang, CHS Kuo, ... Cancers 14 (4), 977, 2022 | 15 | 2022 |
| The co-expression of programmed death-ligand 1 (PD-L1) in untreated EGFR-mutated metastatic lung adenocarcinoma PC Hsu, CW Wang, SCH Kuo, SM Lin, YL Lo, ACC Huang, LC Chiu, ... Biomedicines 8 (2), 36, 2020 | 15 | 2020 |
| The prevalence of PD-L1 expression in lung cancer YC Chang, PC Hsu, SH Li, S Weng, C Kuo, T Yang, C Liu Clin Oncol 4 (1), 1591, 2019 | 14 | 2019 |
Chiao-En WuDivision of Hematology-Oncology, Department of Internal Medicine, Chang Gung Memorial Hospital at Linkou, Chang Gung University College of MedicineVerified email at cgmh.org.tw
